Farmington Hills, Mich., October 31, 2023 ̶ Quest Research Institute, part of the Alcanza Clinical Research site network, today announced the opening of a new research facility, increasing its capacity for Phase I-IV clinical trials and extending its ability to drive progress in innovative therapies for neurological and general medicines, vaccines and rare diseases.
With 10,000 square feet, this state-of-the art facility expands on-site biomarker assessment and in-patient evaluation capabilities to support early phase studies across a range of therapeutic areas and later phase complex neurology trials.
“This expansion enables Quest to take an even greater role in support of the burgeoning pipeline of neurosciences medicines in development,” said Carlos Orantes, Alcanza CEO. “With this facility serving the metropolitan Detroit area and additional planned geographical expansions, we will be better able to provide research opportunities involving promising new medicines to underrepresented communities in urban areas across the U.S.”
Quest will celebrate its official opening with an open house event for the local community on November 14, honoring participants, principal investigators, employees, research and advocacy partners, and hosting its annual Citizen Science© awards with the Global Alzheimer’s Platform Foundation to recognize patient advocates and caregivers. GAP’s Citizen Scientist Awards acknowledge the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases.
About Alcanza Clinical Research
Alcanza Clinical Research is an integrated network of research facilities dedicated to reducing barriers to clinical research participation, especially in underrepresented patient populations. The network is comprised of 17 dedicated research units and 16 additional sites integrated within specialty clinics. These facilities are strategically located across the Southeast, Northeast, and Midwest regions of the United States. Alcanza supports studies that span all clinical trial phases and major therapeutic areas.
About Quest Research Institute
Founded in 1996, Quest Research Institute specializes in Phase I-IV studies across internal medicine, neurology, rare diseases, vaccines and women’s health, with extensive expertise in Alzheimer’s disease, Parkinson’s disease and other movement disorders. Quest is part of the Global Alzheimer’s Platform Foundation network of clinical trial sites, GAP-Net, which is a network of academic and private research sites dedicated to advancing clinical research for Alzheimer’s and other neurodegenerative diseases.
About GAP
The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net).
Contact:
Alcanza Public Relations
pr@alcanzaclinical.com
